特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
951538

ワクチンの世界市場:技術別、疾患別、投与経路別、患者別、地域別の市場規模、トレンド分析、市場シェア、予測:2020年~2027年

Global Vaccine Market Size, by Technology, Disease, Route, Patient, By Region, Trend Analysis, Competitive Market Share & Forecast, 2020-2027

出版日: | 発行: Blueweave Consulting & Research Private Limited | ページ情報: 英文 175 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
ワクチンの世界市場:技術別、疾患別、投与経路別、患者別、地域別の市場規模、トレンド分析、市場シェア、予測:2020年~2027年
出版日: 2020年05月01日
発行: Blueweave Consulting & Research Private Limited
ページ情報: 英文 175 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

ワクチンは、衰弱させた病原体を人に接種することで抗体の形成を促すもので、ポリオや天然痘などの予防に大きな効果を発揮しているほか、がんの免疫療法でも使用されるようになっています。市場拡大の原動力となるのは、エボラ出血熱、インフルエンザ、豚インフルエンザ、肝炎、結核、ジフテリア、髄膜炎菌性疾患や肺炎球菌性疾患などの感染症の拡大、技術的に高度なワクチン、ワクチンデリバリー機器の進歩、予防接種プログラムの拡大などの要因です。その一方でワクチン接種に反対する運動も続いており、世界保健機関(WHO)は、ワクチン接種の忌避を公衆衛生の脅威トップ10の1つに挙げています。

当レポートは、世界のワクチン市場を調査したもので、業界の考察、市場の概要、地域別の分析、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査の枠組み

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 業界の考察

  • 業界のバリューチェーン分析
  • DROC分析
    • 成長要因
    • 抑制要因
    • 市場機会
    • 課題
  • 技術情勢/最新動向
  • 規制の枠組み
  • 各社の市場シェア分析
  • ポーターのファイブフォース分析
  • 新型コロナウイルス感染症(COVID 19)の影響

第5章 世界市場の概要

  • 市場規模と予測:2016~2026年
  • 市場シェアと予測
    • 技術別
      • 生ワクチン
      • トキソイド
      • 組換えワクチン
    • 疾患別
      • 肺炎球菌
      • インフルエンザ
      • DTP
      • ロタウイルス
      • TT
      • ポリオ
      • MMR
      • 水痘
      • デング熱
      • TB、
      • 帯状疱疹
      • 狂犬病
    • 投与経路別
      • IM
      • SC
      • ID
      • 経口
    • 患者別
      • 小児
      • 成人ト
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • ラテンアメリカ
      • 中東・アフリカ

第6章 北米市場

  • 市場規模と予測:2016~2026年
  • 市場シェアと予測
    • 技術別
    • 疾患別
    • 投与経路別
    • 患者別
    • 国別
      • 米国
      • カナダ

第7章 欧州市場

  • 市場規模と予測:2016~2026年
  • 市場シェアと予測
    • 技術別
    • 疾患別
    • 投与経路別
    • 患者別
    • 国別
      • ドイツ
      • 英国
      • フランス
      • イタリア
      • スペイン
      • その他

第8章 アジア太平洋市場

  • 市場規模と予測:2016~2026年
  • 市場シェアと予測
    • 技術別
    • 疾患別
    • 投与経路別
    • 患者別
    • 国別
      • インド
      • 中国
      • 日本
      • 韓国
      • その他

第9章 ラテンアメリカ市場

  • 市場規模と予測:2016~2026年
  • 市場シェアと予測
    • 技術別
    • 疾患別
    • 投与経路別
    • 患者別
    • 国別

第10章 中東およびアフリカ市場

  • 市場規模と予測:2016~2026年
  • 市場シェアと予測
    • 技術別
    • 疾患別
    • 投与経路別
    • 患者別
    • 国別

第11章 企業プロファイル (会社概要、財務マトリックス、主要製品の情勢、主要人物、主な競合企業、連絡先住所、戦略的展望)*

  • Glaxosmithkline PLC
  • Pfizer, Inc
  • Merck & Co., Inc
  • Sanofi Pasteur SA
  • CSL Limited
  • Emergent Biosolutions, Inc
  • Johnson & Johnson
  • Astrazeneca
  • Serum Institute of India Pvt., LTD
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Panacea Biotec, LTD
  • Biological E
  • Bharat Biotech .
  • Other Prominent Players
目次
Product Code: BWC20079

Vaccines, also known as immunizations, vaccinate a debilitating form of illness into a person, so the body starts creating antibodies or protection besides the disease. Real vaccination has eliminated several conditions, like polio and smallpox, with high death rates. The U.S. Food and Drug Administration newly permitted the first vaccine for dengue disease, the foremost cause of illness amid people existing in the tropics and subtropics. Vaccines can also be used after contamination occurs as a therapeutic. This kind of action has lately developed prevalent for use in immuno-oncology for cancer, making up 15 percent of immunotherapies in 2014. The vaccine market lasts to show development, although the anti-vaccine movement. In the U.S., this drive has created an atmosphere of suspicion around vaccines, despite growing indications of vaccines' safety and efficacy. The World Health Organization has named vaccine hesitancy as one of the top ten threats fronting public health this year.

The high occurrence rate of infectious diseases and other chronic conditions in the country. Growing aging population base, along with many initiatives taken by the government of India to expand the provision of vaccines in the nation, will positively influence business development. Companies operating in the vaccines market are concentrating on gripping untapped market potential in the country, thereby pushing the market development.

Moreover, the growth of new and improved immunizations for several diseases is a major factor predictable to push growth. The occurrence of several pipeline drugs is expected to lead the development of the Vaccine Market.

The surge in the occurrence of infectious diseases in France, including measles, has stimulated the demand for vaccines in the country after high CAGR during the forecast period. Furthermore, many labors assumed by the French health bodies to make mindfulness about vaccines through social media platforms, including LinkedIn, Facebook, Twitter, have motivated the acceptance of vaccines in France.

North America accounted for a significant portion of the vaccine market in 2018. The large share of North America in the global vaccines market is credited to the high occurrence of infectious diseases and growing savings by government and non-government organizations for vaccine development. On the other hand, the market in Asia is predicted to list the highest growth during the prediction period. Factors such as the growing healthcare spending and growing disposable income, government initiatives, and the occurrence of a large patient people are motivating the growth of the vaccine market in Asia.

The Asia Pacific region is predictable to bystander the firmest development over the prediction period, credited by the rising target people base with high-unmet clinical needs. In addition, the growing disposable income level and the increasing mindfulness regarding the merits of vaccination in emerging economies of the Asia Pacific region are further predictable to foster market development.

Growth Drivers

Increase in incidence of both viral and bacterial infectious diseases

An escalation in communicable diseases universal, including Ebola, influenza, swine flu, hepatitis, tuberculosis, diphtheria, and meningococcal and pneumococcal diseases, is one of the chief drivers of market growth. Vaccinations are essentially administered to people of different age groups, which strengthens their resistant system during a lifetime and offers protection against dissimilar types of infectious diseases-besides, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), making of technologically advanced vaccines, advancements in vaccine delivery devices, and increase in immunization programs addition the market growth.

Strong Supply backed up by Robust R&D to drive the Vaccines Market

One of the vital and noteworthy drivers for market growth is the growing source of vaccines crosswise the sphere to meet the unmet needs and abide by the immunization policies to eradicate widespread diseases. Pharmaceutical companies, government foundations, international organizations, and hospitals are strongly absorbed in providing cost-effective and regular vaccination to people universal. A government investigation in all the countries has become active in safeguarding that suggested Vaccines at a minimum cost or no cost vaccinate every individual.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary research respondent, By Region
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Vaccine market Industry Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraint
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Technological Landscape/Recent Development
  • 4.4. Regulatory Framework
  • 4.5. Company Market Share Analysis, 2019
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Suppliers
    • 4.6.2. Bargaining Power of Buyers
    • 4.6.3. Threat of New Entrants
    • 4.6.4. Threat of Substitutes
    • 4.6.5. Intensity of Rivalry
  • 4.7. Impact of COVID 19

5. Global Vaccine market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology
      • 5.2.1.1. Live
      • 5.2.1.2. Toxoid
      • 5.2.1.3. Recombinant
    • 5.2.2. By Disease
      • 5.2.2.1. Pneumococcal
      • 5.2.2.2. Influenza
      • 5.2.2.3. DTP
      • 5.2.2.4. Rotavirus
      • 5.2.2.5. TT
      • 5.2.2.6. Polio
      • 5.2.2.7. MMR
      • 5.2.2.8. Varicella
      • 5.2.2.9. Dengue
      • 5.2.2.10. TB,
      • 5.2.2.11. Shingles
      • 5.2.2.12. Rabies
    • 5.2.3. By Route
      • 5.2.3.1. IM
      • 5.2.3.2. SC
      • 5.2.3.3. ID
      • 5.2.3.4. Oral
    • 5.2.4. By Patient
      • 5.2.4.1. Pediatric
      • 5.2.4.2. Adult
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East & Africa

6. North America Vaccine Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Disease
    • 6.2.3. By Route
    • 6.2.4. By Patient
    • 6.2.5. By Country
      • 6.2.5.1. United States
      • 6.2.5.2. Canada

7. Europe Vaccine market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Disease
    • 7.2.3. By Route
    • 7.2.4. By Patient
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. United Kingdom
      • 7.2.5.3. France
      • 7.2.5.4. Italy
      • 7.2.5.5. Spain
      • 7.2.5.6. Rest of Europe

8. Asia Pacific Vaccine Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Disease
    • 8.2.3. By Route
    • 8.2.4. By Patient
    • 8.2.5. By Country
      • 8.2.5.1. India
      • 8.2.5.2. China
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia Pacific

9. Latin America Vaccine Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
      • 9.2.1.1. By Technology
      • 9.2.1.2. By Disease
      • 9.2.1.3. By Route
      • 9.2.1.4. By Patient
      • 9.2.1.5. By Country
      • 9.2.1.5.1. Brazil
      • 9.2.1.5.2. Mexico
      • 9.2.1.5.3. Rest of Latin America

10. Middle East & Africa Vaccine Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
      • 10.2.1.1. By Technology
      • 10.2.1.2. By Disease
      • 10.2.1.3. By Route
      • 10.2.1.4. By Patient
      • 10.2.1.5. By Country
      • 10.2.1.5.1. Saudi Arabia
      • 10.2.1.5.2. UAE
      • 10.2.1.5.3. South Africa
      • 10.2.1.5.4. Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. Glaxosmithkline PLC
  • 11.2. Pfizer, Inc
  • 11.3. Merck & Co., Inc
  • 11.4. Sanofi Pasteur SA
  • 11.5. CSL Limited
  • 11.6. Emergent Biosolutions, Inc
  • 11.7. Johnson & Johnson
  • 11.8. Astrazeneca
  • 11.9. Serum Institute of India Pvt., LTD
  • 11.10. Bavarian Nordic
  • 11.11. Mitsubishi Tanabe Pharma Corporation
  • 11.12. Daiichi Sankyo Company, Limited
  • 11.13. Panacea Biotec, LTD
  • 11.14. Biological E
  • 11.15. Bharat Biotech .
  • 11.16. Other Prominent Players

* Financial details in case of unlisted companies will be available as per data availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.